ArticlePloS one2015
Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- RGS Family Remodeling in Breast Cancer: A Meta-Analysis and Multi-Omics Profiling of Prognostic Biomarkers.Cancer medicine · 2026Pooled it
- CTCF-associated chromatin changes between HOXD1 and HOXD8 contribute to TNBC progression.Experimental & molecular medicine · 2026Article
- β-Catenin-Associated Wnt Signaling and Tumor Microenvironment Markers in Basal Cell Carcinoma Subtypes.Journal of clinical medicine · 2026Article
- Wnt signaling promotes inflammation and EMT-associated gene expression in mesenchymal TNBC.Scientific reports · 2026Article
- A Lamp2a-linked RNA secreted by ADSCs prevents ENO1-lactylation-glycolysis feedback and cell malignant behavior in triple-negative breast cancer.Cell death & disease · 2026Article
- Immune-stromal heterogeneity in breast cancer across diverse ancestries: impact on prognosis and treatment response.NPJ breast cancer · 2025Article
- BUB1B promotes homologous recombination‑mediated DNA damage repair in breast cancer cells through the PI3K/AKT signaling pathway.Oncology reports · 2025Article
- PKD3 localizes to late endosomes to maintain Rab7-dependent endolysosomal homeostasis.iScience · 2025Article
- Evaluating the impact of Xanthoparmelia conspersa extracts on signaling in HeLa cells and exploring their diverse biological activities.Scientific reports · 2024Article
- Canonical WNT/β-catenin signaling upregulates aerobic glycolysis in diverse cancer types.Molecular biology reports · 2024Review
- FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer.EMBO molecular medicine · 2024Article
- Identification of shared gene signatures in major depressive disorder and triple-negative breast cancer.BMC psychiatry · 2024Article
- Identification of Hub of the Hub-Genes From Different Individual Studies for Early Diagnosis, Prognosis, and Therapies of Breast Cancer.Bioinformatics and biology insights · 2024Article
- Expression pattern, prognostic value and potential microRNA silencing of FZD8 in breast cancer.Oncology letters · 2023Article
- Article
- Article
- ELIMINATOR: essentiality analysis using multisystem networks and integer programming.BMC bioinformatics · 2022Article
- Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin αvβ3.Oncogene · 2022Article
- Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Gene co-expression network based on part mutual information for gene-to-gene relationship and gene-cancer correlation analysis.BMC bioinformatics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The canonical Wnt/β-catenin pathway is activated in triple-negative breast cancer (TNBC). The activation of this pathway leads to the expression of specific target genes depending on the cell/tissue context. Here, we analyzed the transcriptome of two different TNBC cell lines to define a comprehensive list of Wnt target genes. The treatment of cells with Wnt3a for 6h up-regulated the expression (fold change > 1.3) of 59 genes in MDA-MB-468 cells and 241 genes in HCC38 cells. Thirty genes were common to both cell lines. Beta-catenin may also be a transcriptional repressor and we found that 18 and 166 genes were down-regulated in response to Wnt3a treatment for 6h in MDA-MB-468 and HCC38 cells, respectively, of which six were common to both cell lines. Only half of the activated and the repressed transcripts have been previously described as Wnt target genes. Therefore, our study reveals 137 novel genes that may be positively regulated by Wnt3a and 104 novel genes that may be negatively regulated by Wnt3a. These genes are involved in the Wnt pathway itself, and also in TGFβ, p53 and Hedgehog pathways. Thorough characterization of these novel potential Wnt target genes may reveal new regulators of the canonical Wnt pathway. The comparison of our list of Wnt target genes with those published in other cellular contexts confirms the notion that Wnt target genes are tissue-, cell line- and treatment-specific. Genes up-regulated in Wnt3a-stimulated cell lines were more strongly expressed in TNBC than in luminal A breast cancer samples. These genes were also overexpressed, but to a much lesser extent, in HER2+ and luminal B tumors. We identified 72 Wnt target genes higher expressed in TNBCs (17 with a fold change >1.3) which may reflect the chronic activation of the canonical Wnt pathway that occurs in TNBC tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.